PURPOSE: To determine the safety and feasibility of combining intratumoral reovirus and radiotherapy in patients with advanced cancer and to assess viral biodistribution, reoviral replication in tumors, and antiviral immune responses. EXPERIMENTAL DESIGN: Patients with measurable disease amenable to palliative radiotherapy were enrolled. In the first stage, patients received radiotherapy (20 Gy in five fractions) plus two intratumoral injections of RT3D at doses between 1 x 10(8) and 1 x 10(10) TCID(50). In the second stage, the radiotherapy dose was increased (36 Gy in 12 fractions) and patients received two, four, or six doses of RT3D at 1 x 10(10) TCID(50). End points were safety, viral replication, immunogenicity, and antitumoral activity. RESULTS: Twenty-three patients with various solid tumors were treated. Dose-limiting toxicity was not seen. The most common toxicities were grade 2 (or lower) pyrexia, influenza-like symptoms, vomiting, asymptomatic lymphopenia, and neutropenia. There was no exacerbation of the acute radiation reaction. Reverse transcription-PCR (RT-PCR) studies of blood, urine, stool, and sputum were negative for viral shedding. In the low-dose (20 Gy in five fractions) radiation group, two of seven evaluable patients had a partial response and five had stable disease. In the high-dose (36 Gy in 12 fractions) radiation group, five of seven evaluable patients had partial response and two stable disease. CONCLUSIONS: The combination of intratumoral RT3D and radiotherapy was well tolerated. The favorable toxicity profile and lack of vector shedding means that this combination should be evaluated in newly diagnosed patients receiving radiotherapy with curative intent. Copyright 2010 AACR.
PURPOSE: To determine the safety and feasibility of combining intratumoral reovirus and radiotherapy in patients with advanced cancer and to assess viral biodistribution, reoviral replication in tumors, and antiviral immune responses. EXPERIMENTAL DESIGN:Patients with measurable disease amenable to palliative radiotherapy were enrolled. In the first stage, patients received radiotherapy (20 Gy in five fractions) plus two intratumoral injections of RT3D at doses between 1 x 10(8) and 1 x 10(10) TCID(50). In the second stage, the radiotherapy dose was increased (36 Gy in 12 fractions) and patients received two, four, or six doses of RT3D at 1 x 10(10) TCID(50). End points were safety, viral replication, immunogenicity, and antitumoral activity. RESULTS: Twenty-three patients with various solid tumors were treated. Dose-limiting toxicity was not seen. The most common toxicities were grade 2 (or lower) pyrexia, influenza-like symptoms, vomiting, asymptomatic lymphopenia, and neutropenia. There was no exacerbation of the acute radiation reaction. Reverse transcription-PCR (RT-PCR) studies of blood, urine, stool, and sputum were negative for viral shedding. In the low-dose (20 Gy in five fractions) radiation group, two of seven evaluable patients had a partial response and five had stable disease. In the high-dose (36 Gy in 12 fractions) radiation group, five of seven evaluable patients had partial response and two stable disease. CONCLUSIONS: The combination of intratumoral RT3D and radiotherapy was well tolerated. The favorable toxicity profile and lack of vector shedding means that this combination should be evaluated in newly diagnosed patients receiving radiotherapy with curative intent. Copyright 2010 AACR.
Authors: Wen Qing Yang; Xueqing Lun; Cheryl Ann Palmer; M Elizabeth Wilcox; Huong Muzik; Zhong Qiao Shi; Richard Dyck; Matt Coffey; Brad Thompson; Mark Hamilton; Sandra G Nishikawa; Penny M A Brasher; Kevin Fonseca; David George; N Berry Rewcastle; Randal N Johnston; Doug Stewart; Patrick W K Lee; Donna L Senger; Peter A Forsyth Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Jennifer H Tai; John V Williams; Kathryn M Edwards; Peter F Wright; James E Crowe; Terence S Dermody Journal: J Infect Dis Date: 2005-03-08 Impact factor: 5.226
Authors: Karishma Rajani; Christopher Parrish; Timothy Kottke; Jill Thompson; Shane Zaidi; Liz Ilett; Kevin G Shim; Rosa-Maria Diaz; Hardev Pandha; Kevin Harrington; Matt Coffey; Alan Melcher; Richard Vile Journal: Mol Ther Date: 2015-08-27 Impact factor: 11.454
Authors: E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2015-02-27 Impact factor: 3.167
Authors: Eleni M Karapanagiotou; Victoria Roulstone; Katie Twigger; Mercel Ball; Maryanne Tanay; Chris Nutting; Kate Newbold; Martin E Gore; James Larkin; Konstantinos N Syrigos; Matt Coffey; Brad Thompson; Karl Mettinger; Richard G Vile; Hardev S Pandha; Geoff D Hall; Alan A Melcher; John Chester; Kevin J Harrington Journal: Clin Cancer Res Date: 2012-02-07 Impact factor: 12.531
Authors: Chandini M Thirukkumaran; Zhong Qiao Shi; Gerard J Nuovo; Joanne Luider; Karen A Kopciuk; Yuan Dong; Ahmed A Mostafa; Satbir Thakur; Kathy Gratton; Ailian Yang; Alex C Chin; Matt C Coffey; Victor H Jimenez-Zepeda; Douglas Stewart; Marta Chesi; P Leif Bergsagel; Don Morris Journal: Blood Adv Date: 2019-03-12
Authors: Don G Morris; Xiaolan Feng; Lisa M DiFrancesco; Kevin Fonseca; Peter A Forsyth; Alexander H Paterson; Matt C Coffey; Brad Thompson Journal: Invest New Drugs Date: 2012-08-12 Impact factor: 3.850